India talks tough to end trade margins row as drug shortages loom
This article was originally published in SRA
Faced with the prospect of continued disruptions to shipments of essential medicines in India from a disagreement over trade margins, the country's department of pharmaceuticals (DoP) has taken a tough stance, urging state governments to ensure smooth supplies, including by invoking the Essential Commodities Act if necessary.
You may also be interested in...
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.
Pharma appears to be treading carefully when it comes to research preprints but COVID-19 has spotlighted the role of these pre-peer-reviewed papers during public health emergencies.